• EN
  • DE
Pharma-Marketing.com Pharma-Marketing.com
  • Industry
  • Digital
  • Channels
  • People
  • Glossary
  • EN
  • DE
Gilead Extends Tender Offer for Arcellx

Gilead Extends Tender Offer for Arcellx

Gilead has extended its tender offer to acquire Arcellx until April 24, 2026. The offer remains $115 per share in cash plus a CVR.

IQVIA: German pharma market up in value in 2025, volumes slightly down

IQVIA: German pharma market up in value in 2025, volumes slightly down

IQVIA reports 5.7% sales growth in Germany’s pharma market in 2025, while volumes slipped by 0.7%. In pharmacies, Rx grew faster than OTC.

Gilead to acquire Ouro Medicines for clinical BCMAxCD3 program

Gilead to acquire Ouro Medicines for clinical BCMAxCD3 program

Gilead Sciences plans to buy Ouro Medicines for up to $2.175bn, adding OM336, a clinical BCMAxCD3 T cell engager for autoimmune diseases.

Hims & Hers shifts US weight loss strategy with Novo Nordisk deal

Hims & Hers shifts US weight loss strategy with Novo Nordisk deal

Hims & Hers is refocusing its US weight loss business and teaming up with Novo Nordisk, prioritizing access to a wider set of FDA-approved GLP-1 drugs.

Sandoz launches azelastine/fluticasone nasal spray in Germany and Switzerland

Sandoz launches azelastine/fluticasone nasal spray in Germany and Switzerland

Sandoz has launched an azelastine/fluticasone nasal spray in Germany and Switzerland, expanding access to a fixed-dose allergy treatment option.

Sandoz partners with Samsung Bioepis on up to five biosimilars

Sandoz partners with Samsung Bioepis on up to five biosimilars

Sandoz and Samsung Bioepis agreed to collaborate on up to five biosimilar assets, starting with an early-stage vedolizumab biosimilar program.

BC Partners and Bpifrance complete acquisition of Biogaran

BC Partners and Bpifrance complete acquisition of Biogaran

BC Partners and Bpifrance have completed the acquisition of Biogaran from Servier. Erick Roche is set to become CEO by the end of March 2026.

Hikma reports revenue and core profit growth, launches buyback and reshuffles leadership

Hikma reports revenue and core profit growth, launches buyback and reshuffles leadership

Hikma posted 2025 revenue and core profit growth, lifted its dividend and announced a US$250m share buyback plus immediate leadership changes.

Esperion to acquire Corstasis to add Enbumyst to its CV portfolio

Esperion to acquire Corstasis to add Enbumyst to its CV portfolio

Esperion has signed a definitive deal to acquire Corstasis. The transaction adds Enbumyst, an FDA-approved bumetanide nasal spray for edema.

BioMarin withdraws hemophilia gene therapy Roctavian

BioMarin withdraws hemophilia gene therapy Roctavian

BioMarin is withdrawing Roctavian from the market after divestiture efforts failed, booking about $240M in Q4 2025 charges tied to the exit.

Novo Nordisk to invest €432m in Athlone manufacturing site

Novo Nordisk to invest €432m in Athlone manufacturing site

Novo Nordisk will invest €432m in its Athlone, Ireland, tabletting plant to add manufacturing capacity for current and future oral GLP-1 therapies.

GSK agrees to acquire 35Pharma, adding pulmonary hypertension asset HS235

GSK agrees to acquire 35Pharma, adding pulmonary hypertension asset HS235

GSK has agreed to acquire Canada’s 35Pharma for $950m in cash, gaining HS235, an activin signalling inhibitor being developed for pulmonary hypertension.

Novo Nordisk partners with Vivtex on oral biologics

Novo Nordisk partners with Vivtex on oral biologics

Novo Nordisk and Vivtex will work on oral biologics for obesity and diabetes. Vivtex is eligible for up to US$2.1 billion plus tiered royalties.

Merck reshapes business ahead of Keytruda patent expiry

Merck reshapes business ahead of Keytruda patent expiry

Merck & Co. is splitting operations into two divisions to prepare for Keytruda’s 2030 patent expiry and to broaden its portfolio.

medac Group exits diagnostics business to focus on pharma

medac Group exits diagnostics business to focus on pharma

medac Group is divesting its diagnostics activities via a management buy-out to focus on pharma. The business will continue as mevida Diagnostika.

Hameln to host second nursing congress on the future of care

Hameln to host second nursing congress on the future of care

Sana Klinikum Hameln-Pyrmont will host the “Pflege bewegt” nursing congress on 16 April 2026 in Hameln, focusing on future nursing practice.

DMEA sparks Award 2026 opens call for digital health theses

DMEA sparks Award 2026 opens call for digital health theses

DMEA has opened applications for the sparks Award 2026, honouring bachelor’s and master’s theses on healthcare digitalisation. Deadline: 31 January 2026.

WEFRA MEDIAPLUS GLOBAL HEALTH Sets New Standards in Healthcare Media

WEFRA MEDIAPLUS GLOBAL HEALTH Sets New Standards in Healthcare Media

With WEFRA MEDIAPLUS GLOBAL HEALTH, Mediaplus Group and WEFRA LIFE GROUP combine their strengths to deliver scalable, international healthcare campaigns. The joint venture connects global strategies with strong local execution.

New care concept strengthens outpatient follow-up for cardiac patients

New care concept strengthens outpatient follow-up for cardiac patients

Novartis Germany and the Ambulatory Heart Center Kassel are launching a new outpatient care concept to support structured follow-up care for cardiac patients, with a focus on LDL cholesterol. The goal is to sustainably reduce risk factors through standardized treatment pathways.

Drug spending rises, pharmacy remuneration stagnates

Drug spending rises, pharmacy remuneration stagnates

Statutory health insurance drug spending rose as forecast in 2025. Pharmacy remuneration, however, continues to stagnate despite rising costs and declining prescription volumes.

1 2 3 … 7 Next page

Advertisement

A Partner For Successful Marketing in Pharma & Healthcare

8awake, the specialized agency for pharma and healthcare marketing, supports you with the successful development and execution of winning campaign activities in healthcare.


Stay up to date!

Subscribe to our free Pharma-Marketing-Newsletter.

Data-privacy(Required)

Advertisement

Only a few physicians log in to your website?

A login that sets a new standard for authenticating HCPs and equips your marketing team with everything they need to successfully promote Rx-products. Learn more on DocID.pro

  • Privacy Policy
  • Imprint
Pharma-Marketing.com

Copyright 2025 Pharma-Marketing.com.
All rights reserved.

Data-privacy settings

We use cookies on our website to improve the service we offer. The information helps us to understand how our visitors use our site. But some cookies are even necessary for the proper function of the website. These are marked as "essential" in the details.

Accept Essential cookie
Name Data-privacy settings
Provider 8awake GmbH
Purpose Cookie is used for storing your answer on this banner. So that we won't ask you again.
Privacy policy Privacy policy
Cookies 8awake_data_privacy
Cookie expiration 180 days
Accept
Name Google Analytics
Provider Google LLC
Purpose Cookies by Google are used for website analytics. Generates statistical data on how the visitor uses the website.
Privacy policy Privacy policy
Cookies _ga, _gat, _gid
Cookie expiration 2 Years
Accept
Name Google Ads
Provider Google LLC
Purpose Cookies by Google Ads are used for advertising and targeting purpose.
Privacy policy Privacy policy
Cookies __gsas, __gpi, __gpi_optout, NID, DSID, test_cookie, id, __gads
Cookie expiration 2 Years
Accept
Name Facebook
Provider Facebook Inc.
Purpose Cookies by Facebook are used for advertising and marketing activities. Generates statistical data on how the visitor uses the website.
Privacy policy Privacy policy
Cookies _fbp, fr
Cookie expiration 2 Years
Save settings
Custom settings
Accept all